Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822474 | 0.90 | ATM (0.51) | ATMNAMPTATRALPLCYP17A1 | |
| SCHEMBL31145167 | 0.90 | ATM (0.51) | ATMNAMPTATRALPLCYP17A1 | |
| SCHEMBL4741552 | 0.87 | ATM (0.38) | ATMNAMPTATRALPLCYP17A1 | |
| SCHEMBL6928387 | 0.84 | GRM5 (0.52) | NAMPTGRM5CYP17A1 | |
| SCHEMBL31093763 | 0.83 | NAMPT (0.47) | NAMPTGRM5ATRCYP17A1 | |
| SCHEMBL14395723 | 0.83 | NAMPT (0.47) | NAMPTGRM5ATRCYP17A1 | |
| SCHEMBL4745642 | 0.79 | ATM (0.42) | ATMNAMPTGRM5ATRCYP17A1 | |
| SCHEMBL14428036 | 0.79 | NAMPT (0.54) | NAMPTATRCYP17A1 | |
| SCHEMBL27077040 | 0.79 | NAMPT (0.44) | NAMPTALPLCYP17A1 | |
| SCHEMBL4745294 | 0.78 | L3MBTL1 (0.48) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | ATM 707/4885NAMPT 1276/4885GRM5 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.